Eric G Mohler1, Stanley R Franklin, Lynne E Rueter. 1. Neuroscience Drug Discovery, AbbVie, 1 N. Waukegan Rd., Bldg AP-9A, North Chicago, IL, 60064-6125, USA, eric.mohler@abbvie.com.
Abstract
RATIONALE: Neuronal α4β2* nicotinic acetylcholine receptors mediate cognition, pain, and the discriminative and reinforcing effects of nicotine. In addition to traditional orthosteric agonists, α4β2* positive allosteric modulators (PAMs) have recently been identified. With increased subtype selectivity relative to agonists, PAMs administered alone or in combination with low-dose α4β2* agonists may be used as powerful tools for increasing our understanding of α4β2* pharmacology. OBJECTIVES: The present experiments tested the nicotine discriminative-stimulus effects of the α4β2* PAM NS9283 (A-969933) in the presence and absence of low-dose nicotine or nicotinic subtype-selective agonist. METHODS: Rats were trained to discriminate 0.4 mg/kg nicotine from saline in a two-lever drug discrimination paradigm. In subsequent generalization tests, rats were administered nicotine, the α4β2*-preferring agonist ABT-594, and NS9283, alone or in two-drug combinations. RESULTS: Nicotine and ABT-594 showed dose-dependent nicotine generalization. NS9283 alone resulted in a non-significant increase in nicotine-appropriate lever selection. Combination of non-effective doses of nicotine or ABT-594 with escalating doses of NS9283 resulted in a complete conversion to 100 % nicotine-appropriate choice in the case of nicotine combination and incomplete, though significant, generalization for ABT-594. CONCLUSIONS: The α4β2* PAM NS9283 alone did not produce nicotine-like discriminative effects, but did demonstrate dose-related increases in nicotine lever choice when combined with a non-effective dose of nicotine or the α4β2* agonist ABT-594. This finding provides confirmation of the positive allosteric modulating effect of NS9283 in a functional in vivo paradigm. NS9283 is a potentially valuable tool for studying the role of α4β2* receptors in various nicotinic acetylcholine receptor-related functions.
RATIONALE: Neuronal α4β2* nicotinic acetylcholine receptors mediate cognition, pain, and the discriminative and reinforcing effects of nicotine. In addition to traditional orthosteric agonists, α4β2* positive allosteric modulators (PAMs) have recently been identified. With increased subtype selectivity relative to agonists, PAMs administered alone or in combination with low-dose α4β2* agonists may be used as powerful tools for increasing our understanding of α4β2* pharmacology. OBJECTIVES: The present experiments tested the nicotine discriminative-stimulus effects of the α4β2* PAM NS9283 (A-969933) in the presence and absence of low-dose nicotine or nicotinic subtype-selective agonist. METHODS:Rats were trained to discriminate 0.4 mg/kg nicotine from saline in a two-lever drug discrimination paradigm. In subsequent generalization tests, rats were administered nicotine, the α4β2*-preferring agonist ABT-594, and NS9283, alone or in two-drug combinations. RESULTS:Nicotine and ABT-594 showed dose-dependent nicotine generalization. NS9283 alone resulted in a non-significant increase in nicotine-appropriate lever selection. Combination of non-effective doses of nicotine or ABT-594 with escalating doses of NS9283 resulted in a complete conversion to 100 % nicotine-appropriate choice in the case of nicotine combination and incomplete, though significant, generalization for ABT-594. CONCLUSIONS: The α4β2* PAM NS9283 alone did not produce nicotine-like discriminative effects, but did demonstrate dose-related increases in nicotine lever choice when combined with a non-effective dose of nicotine or the α4β2* agonist ABT-594. This finding provides confirmation of the positive allosteric modulating effect of NS9283 in a functional in vivo paradigm. NS9283 is a potentially valuable tool for studying the role of α4β2* receptors in various nicotinic acetylcholine receptor-related functions.
Authors: D L Donnelly-Roberts; P S Puttfarcken; T A Kuntzweiler; C A Briggs; D J Anderson; J E Campbell; M Piattoni-Kaplan; D G McKenna; J T Wasicak; M W Holladay; M Williams; S P Arneric Journal: J Pharmacol Exp Ther Date: 1998-05 Impact factor: 4.030
Authors: A W Bannon; M W Decker; M W Holladay; P Curzon; D Donnelly-Roberts; P S Puttfarcken; R S Bitner; A Diaz; A H Dickenson; R D Porsolt; M Williams; S P Arneric Journal: Science Date: 1998-01-02 Impact factor: 47.728
Authors: Ayman K Hamouda; Malia R Bautista; Lois S Akinola; Yasmin Alkhlaif; Asti Jackson; Moriah Carper; Wisam B Toma; Sumanta Garai; Yen-Chu Chen; Ganesh A Thakur; Christie D Fowler; M Imad Damaj Journal: Neuropharmacology Date: 2021-04-18 Impact factor: 5.273